The oligometastatic state—separating truth from wishful thinking
David A. Palma(Western University), Ralph R. Weichselbaum(University of Chicago), Joseph K. Salama(University of California San Diego), Tom Treasure(University College London), Suresh Senan(Amsterdam Neuroscience), Ramaswamy Govindan(Washington University in St. Louis), Simon S. Lo(University Hospitals Seidman Cancer Center)
Cited by 280
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k